Tracing management and epidemiological characteristics of close contact COVID-19 in primary health care

Hanardi, Dwi Yulianingsih Putri; Rochmawati, Erna

doi:10.15562/bmj.v11i3.3705

Cited by 4 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The virus is thought to spread from person to person by droplets released by an infected individual while coughing, sneezing, or talking. Contacting one's lips, nose, or eyes after touching a surface with the virus on it is a less common way to transmit the disease [8][9][10][11] .…”

Section: Introductionmentioning

confidence: 99%

Curcumin from Curcuma longa L. as Dual Inhibitors Against Indonesian SARS-CoV-2 Isolates: A Molecular Docking Study

Nidom¹,

Ansori²,

Nidom³

et al. 2023

Pharmacogn J.

View full text Add to dashboard Cite

Using Lipinski's rule of five on the SCFBIO web server (http://www.scfbio-iitd. res.in/software/ drugdesign/lipinski.jsp), curcumin was utilized for further drug-likeness analysis. It was regarded as a successful forecast when two minimal guidelines ABSTRACT COVID-19 has become a global pandemic since 2020. The search for promising drugs based on the abundant herbal ingredients in Indonesia is one of the breakthroughs. Curcumin is a chemical compound with various potentials such as antioxidant, anti-inflammatory and antiviral. We conducted a molecular docking analysis to determine the potential of curcumin against SARS-CoV-2 non-structural and structural proteins, such as the main protease and spike protein. This study used the compound of curcumin (PubChem CID: 969516) from Curcuma longa L. or turmeric and two Indonesian SARS-CoV-2 isolates that have been deposited in the GISAID database (hCoV-19/Indonesia/JI-PNF-217315/2021 -EPI_ ISL_12777089 or lineage B.1.617.2 and hCoV-19/Indonesia/JI-PNF-211373/2021 -EPI_ISL_6425649 or lineage B.1.470). In addition, we used molnupiravir (PubChem CID: 145996610) as a drug control. We performed molecular docking analysis with PyRx software 0.9.9 (academic license) and visualization of molecular docking results with PyMOL software 2.5.4 (academic license). The results of this study found that curcumin had good potential against main protease and spike protein compared to the drug (control). In summary, we suggested that curcumin is a potential drug candidate against SARS-CoV-2. However, there is a need for future wet laboratory-based pre-clinical research such as in vitro and in vivo.

show abstract

Section: Introductionmentioning

confidence: 99%

Curcumin from Curcuma longa L. as Dual Inhibitors Against Indonesian SARS-CoV-2 Isolates: A Molecular Docking Study

Nidom¹,

Ansori²,

Nidom³

et al. 2023

Pharmacogn J.

View full text Add to dashboard Cite

show abstract

Meridine and Xestosaprol M have Potential Anti-Virus Resembling Remdesivir

Setianingsih,

Yatmasari,

Ilmawan

2023

RJPT

View full text Add to dashboard Cite

The rise and fall of the COVID-19 wave continue to be watched because the right antiviral drug has not yet been found. Remdesivir is an antiviral drug that is much sought after, especially when the number of COVID-19 cases is spreading worldwide. Until now, the US Food and Drug Administration (FDA) and the Drugs Controller General of India (DCGI) have confirmed the treatment for COVID-19 infection is remdesivir; because of that, remdesivir is very expensive and difficult to find, so that other similar or alternative drugs are needed. Even better ones with better potential too. Based on studies, insilico meridine and xestosaprol M have the same potential as remdesivir as an anti-COVID-19 virus.

show abstract

Epitope-based Vaccine Design from Alpha and Beta Variant of SARS-CoV-2: An Immunoinformatics Approach

Pratama,

Sumantri,

Fauziyah Rahman

et al. 2023

RJPT

View full text Add to dashboard Cite

Coronavirus disease 2019, also known as COVID-19, is a respiratory disease. Symptoms of COVID-19 include fever, dry cough, inflammation of the throat area, loss of smell, and even breathing difficulty. COVID-19 is caused by SARS-CoV-2 infection, a virus that is a member of the coronavirus family. The SARS-CoV-2 structure consists of S (spike), M (membrane), E (envelope), and N (nucleocapsid) protein. Two SARS-CoV-2 variants, namely alpha (B.1.1.7) and beta (B.1.351) variants are considered a variant of concern (VoC) due to their increased infectivity. It has been reported that the vaccine's efficacy against these two variants decreased. The purpose of this study is to compare epitopes from S and N proteins of alpha and beta variants to find the most suitable vaccine candidate through reverse vaccinology. In this study, physicochemical properties, antigenicity, and epitope prediction, as well as molecular docking of the epitope and B cell receptor, 5IFH, were done. The result suggested that the epitope from S protein was more suitable as a vaccine candidate. S protein epitope has a lower global energy value which means that it can bind to 5IFH more spontaneously compared to N protein epitopes. The most suitable vaccine candidate for the alpha variant is Pep_B, with a global energy value of -48.77 kcal/mol, and Pep_F, for the beta variant, with a global energy value of -61.61 kcal/mol. These results would recommend the epitopes to be used in further COVID-19 vaccine development.

show abstract

Tracing management and epidemiological characteristics of close contact COVID-19 in primary health care

Cited by 4 publications

References 16 publications

Curcumin from Curcuma longa L. as Dual Inhibitors Against Indonesian SARS-CoV-2 Isolates: A Molecular Docking Study

Curcumin from Curcuma longa L. as Dual Inhibitors Against Indonesian SARS-CoV-2 Isolates: A Molecular Docking Study

Meridine and Xestosaprol M have Potential Anti-Virus Resembling Remdesivir

Epitope-based Vaccine Design from Alpha and Beta Variant of SARS-CoV-2: An Immunoinformatics Approach

Contact Info

Product

Resources

About